PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Tirzepatide - Diabetes Mellitus

PAD Profile : Tirzepatide - Diabetes Mellitus

Brand Names Include :
Mounjaro

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Injection
Important Information :
3rd line where dulaglutide or semaglutide are unsuitable / unavailable
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves tirzepatide, a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for treating type 2 diabetes in line with the recommendations made in NICE TA924.

Tirzepatide will be given a GREEN traffic light status for this indication.

Dulaglutide remains the preferred choice among GLP-1 options for weekly injections and semaglutide stands as an alternative to dulaglutide for weekly injections.

Please consider tirzepatide as a third line option to dulaglutide and semaglutide weekly injection, only if:

·         dulaglutide and semaglutide are unsuitable.

or

the supply of dulaglutide and semaglutide weekly injections is unavailable.

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More